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Abstract 
X-linked severe combined immunodeficiency (SCID-X1) is caused by mutations in the gene 
encoding the interleukin-2 receptor γ chain (IL2RG), and is characterized by profound defects 
in T-, B- and NK-cell functions. Previous gene therapy clinical trials based on hematopoietic 
stem/progenitor cells (HSPCs) genetically corrected with MLV-derived retroviral vectors 
showed restoration of T-cell immunity but resulted in vector-induced leukemia through 
insertional mutagenesis. The use of an enhancer-less MLV vector to deliver the IL2RG gene 
caused no adverse events while retaining a significant clinical benefit. To increase the 
efficacy of gene therapy and further reduce potential genotoxicity, we developed a SIN 
lentiviral vector carrying a codon-optimized human IL2RG cDNA under the control of the 
human EF1α-S promoter. Codon optimization resulted in a 3-fold increase in mRNA and a 
1.5-fold increase in protein expression per integrated vector copy. The performance of the 
vector was demonstrated in vitro by the restoration of a normal level of IL2RG mRNA or 
protein in a IL2RG-deficient T-cell line, patient-derived EBV-immortalized B-cells and 
mobilized CD34+ HSPCs, with no impact on viability or clonogenic capacity. An in vitro 
immortalization assay (IVIM) showed a safe genotoxic profile, while the in vivo safety and 
efficacy of the vector was tested it in a preclinical model of SCID-X1 gene therapy based on 
transplantation of genetically corrected Lin- cells from IL2rg-/- donor mice into lethally-
irradiated IL2rg-/--Rag2-/- recipients. The study showed restoration of T, B and NK cell counts 
in bone marrow and peripheral blood, normalization of lymphoid organs (thymus and spleen) 
and a frequency of hematopoietic abnormalities comparable to that of control animals six 
months after transplantation. An extensive insertion site analysis carried out in bone marrow, 
thymus and peripheral blood of individual or groups of animals showed the expected 
genomic integration profile and no signs of clonal dominance in transduced cells. 
Interestingly, analysis of >100,000 integration sites in pre- and post-transplant murine cells 
showed that lentiviral vectors target at high frequency a substantially different set of genes 
compared to human CD34+ cells, uncovering the limits in the predictive power of mouse-
based genotoxicity studies. These studies will enable a multicenter phase-I/II clinical trial 
aimed at establishing the safety and clinical efficacy of lentiviral vector-mediated gene 
therapy for SCID-X1 in infants after non-myeloablative conditioning, and sustained 
restoration of both T- and B-cell immunity. 
 
